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demonstrated that IFX-treated patients could gain economic
beneﬁt by retaining employability over time.
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OBJECTIVE: To assess the preference of Brazilians for drugs
with different dosing and methods of application to treat chronic
diseases, such as osteoporosis. The assessed product types were:
once-monthly oral, injection once every three months, and
once-yearly injection. METHODS: Quantitative study per-
formed through personal and individual interviews. A represen-
tative sample of the study population (N = 392 subjects) was
used. Subjects over 45 years old were interviewed. A 14-item
structured questionnaire was used. A card with the drug charac-
teristics (dosing, cares of administration, side effects and annual
treatment cost) was shown to the interviewed subjects.
RESULTS: Fourty-four percent of the interviewed subjects were
male and 56% were female. Sixty percent of the interviewed
subjects were between 45 and 59 years old, and the other 40%
were 60 years old or more. Fourteen percent of the interviewed
subjects belonged to the Brazilian socioeconomic classiﬁcation
“A”, followed by 39% in the classiﬁcation “B”, and 47% in the
classiﬁcation “C”. Twenty-eight percent had higher education,
followed by 29% with secondary education, and 42% with
primary education. Ninety-three percent of the interviewed sub-
jects do not usually take injection drugs. For treatment of chronic
diseases, 72% of the patients prefer oral drugs, 16% prefer
injection drugs diluted in serum, 9% prefer injection drugs, and
3% did not inform their preference. These percentages remained
the same when dosing, side effects and prices were disclosed.
83% of the patients who chose oral drug did it so by convenience
of the dosing, 21% of them also think that oral drugs have fewer
side effects than injection drugs. Generically comparing (not
considering the card with product proﬁles) oral and injection
drugs, 78% of the population prefer oral treatments. CONCLU-
SION: If patients are given the chance to choose between oral or
injection drugs to treat chronic diseases, 78% prefer oral drugs
instead of injection ones.
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OBJECTIVE: To determine the differences in the patterns and
costs of health care utilization between recipients with Rheuma-
toid Arthritis (RA) with versus without comorbid depression
enrolled in a state Medicaid program. METHODS: A retrospec-
tive cross-sectional analysis of a de-identiﬁed state Medicaid
fee-for-service administrative claims dataset was conducted. The
target population included recipients between 15–64 years old
who were continuously eligible for beneﬁts between January 1,
2002 and December 31, 2003. Recipients with at least one
medical services claim with a primary diagnosis of RA in 2002
were selected. The sample was then dichotomized between those
with versus without a medical claim with a primary diagnosis of
depression during 2002. Data from calendar year 2003 was used
to compare the patterns of RA-related ofﬁce services and pre-
scription medication utilization and related costs between the
two groups. RESULTS: There were 763 recipients identiﬁed with
RA, of whom 244 (31.9%) had comorbid depression. A signiﬁ-
cantly (p < 0.05) higher proportion of recipients 21–44 years of
age (41.9%), females (34.4%), and whites (32.0%) with RA had
comorbid depression. Negative binomial regression controlling
for demographic variables and comorbidities showed the fre-
quency of ofﬁce visit utilization was signiﬁcantly (p < 0.05) lower
for recipients with comorbid depression than those without
depression. A signiﬁcantly (p < 0.05) higher proportion of recipi-
ents without depression than with depression had a claim for a
DMARD (49.4% versus 31.9%) and a biologic agent (17.0%
versus 10.0%). The average annual amount paid by Medicaid
per recipient for the use of ofﬁce services and prescription medi-
cations was signiﬁcantly (p < 0.05) higher for recipients without
depression ($2914) than with depression ($2049). CONCLU-
SION: Roughly one-third of the recipients with RA had comor-
bid depression. The use of primary care ofﬁce services and
prescription medications that can slow the progression of RA
was lower among recipients with depression than without
depression.
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OBJECTIVE: Acetaminophen (paracetamol) and non-steroidal
anti-inﬂammatory drugs (NSAIDs) are common prescription
and nonprescription medications for osteoarthritis (OA). British
Columbia (BC) PharmaNet data contains one record for every
prescription. The National Population Heath Survey (NPHS)
includes prescription and nonprescription medications, but the
BC sample is small. Our objective is to explore the utility of large
prescription-only databases in studying drugs with nonprescrip-
tion forms. We compare acetaminophen and NSAIDs according
to OA and disease duration (OAD), and compare results from
NPHS versus PharmaNet. METHODS: Medications in the 2002/
2003 NPHS (Canada = 11717, BC = 1101) refer to the two days
before the interview. Statistics Canada classiﬁed responses by
ATC. OA was self-reported. In Medical Services Plan (MSP) data,
ICD-9 codes determined OA. PharmaNet (n = 100,000) was
linked to MSP, and weighted according to the 2003 BC popula-
tion. Medication use from PharmaNet/NPHS was compared
by age, sex and OAD. RESULTS: PharmaNet: acetaminophen
ranged from 0.04% in ages 0–49 without OA to 6.7% in 50–59
with OAD > 6 years. OAD increased use. NSAID ranged from
0.43% in 0–49 without OA to 10.7% in 70+ with OAD > 6
years. OAD and older age increased use. NPHS: acetaminophen
ranged from 5.1% to 15.8%. OA disease increased use. NSAID
ranged from 8.9% in 0–49 without OA to 32.6% in 70+ with
OAD > 6 years. OAD and older age increased use. The ratio of
acetaminophen in NPHS/PharmaNet ranged from 1.25 (50–59
with OAD > 6 years) to 175.7 (0–49 without OA). The ratio of
NSAID ranged from 3.04 to 20.6. CONCLUSION: In
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